Compare HIMX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | ADPT |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2006 | 2019 |
| Metric | HIMX | ADPT |
|---|---|---|
| Price | $20.63 | $13.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $17.78 |
| AVG Volume (30 Days) | ★ 4.9M | 1.5M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $14.94 | $3.98 |
| Revenue Next Year | $7.79 | $22.72 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $6.85 | $8.50 |
| 52 Week High | $21.80 | $20.76 |
| Indicator | HIMX | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 41.50 |
| Support Level | $7.63 | $12.22 |
| Resistance Level | N/A | $13.45 |
| Average True Range (ATR) | 1.44 | 0.75 |
| MACD | 0.89 | -0.09 |
| Stochastic Oscillator | 89.48 | 5.20 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.